Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Symptomatic moderate or severe chronic GVHD patients in need of a change of systemic immunosuppressant (IS) therapy~* Women of child bearing potential must have a negative pregnancy test and use reliable methods of contraception~Exclusion Criteria:~* Clinically significant medical conditions including active or uncontrolled infections, new or recurrent malignancy, serious cardiac, pulmonary, or renal disease, and uncontrolled diabetes.~* Karnofsky Performance Score \< 60.~* Immunosuppressant therapies other than allowed background therapy~* Anti-arrhythmic and heart rate lowering drugs.~* Any other circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ponesimod (Type: EXPERIMENTAL): Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).